PMID- 30863012
OWN - NLM
STAT- MEDLINE
DCOM- 20190731
LR  - 20200225
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 13
DP  - 2019
TI  - Profile of semaglutide in the management of type 2 diabetes: design, development, 
      and place in therapy.
PG  - 731-738
LID - 10.2147/DDDT.S165372 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity 
      and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia 
      are the main pitfalls of previous treatments for T2DM. New therapies have been 
      designed with the aim of improving the results in efficacy and quality of life. 
      Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase 
      glucose-dependent insulin secretion, decrease gastric emptying, and reduce 
      postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and 
      Drug Administration and European Medicines Agency was semaglutide. This review 
      describes its pharmacology, core clinical data coming from the randomized 
      controlled trials included in the development program, proven cardiovascular 
      benefits, safety issues, and precautions for the use of semaglutide in special 
      populations. Additionally, an overview of the positioning of semaglutide in T2DM 
      therapy and practical issues regarding semaglutide initiation are offered.
FAU - Gomez-Peralta, Fernando
AU  - Gomez-Peralta F
AD  - Endocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain, 
      fgomezperalta@gmail.com.
FAU - Abreu, Cristina
AU  - Abreu C
AD  - Endocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain, 
      fgomezperalta@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190220
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glucagon-Like Peptides/chemical synthesis/chemistry/*pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/chemistry/*pharmacology
PMC - PMC6388990
OTO - NOTNLM
OT  - clinical practice
OT  - pharmacological treatment
OT  - safety
OT  - semaglutide
OT  - type 2 diabetes
COIS- Disclosure Fernando Gomez-Peralta has received research support from Sanofi, Novo 
      Nordisk, Boehringer Ingelheim, and Eli Lilly, has taken part in advisory boards 
      for Sanofi, Novo Nordisk, and AstraZeneca Pharmaceuticals LP, and has acted as a 
      speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, Novartis, Bristol-Myers 
      Squibb Company, Eli Lilly, and AstraZeneca Pharmaceuticals LP. Cristina Abreu has 
      received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim 
      Pharmaceuticals, and Lilly, and has acted as a speaker for Sanofi, Novo Nordisk, 
      Boehringer Ingelheim Pharmaceuticals, AstraZeneca Pharmaceuticals LP, and 
      Bristol-Myers Squibb Co. The authors report no other conflicts of interest in 
      this work.
EDAT- 2019/03/14 06:00
MHDA- 2019/08/01 06:00
PMCR- 2019/02/20
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/08/01 06:00 [medline]
PHST- 2019/02/20 00:00 [pmc-release]
AID - dddt-13-731 [pii]
AID - 10.2147/DDDT.S165372 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2019 Feb 20;13:731-738. doi: 10.2147/DDDT.S165372. 
      eCollection 2019.